Propanc Biopharma signed a memorandum of understanding with Avance Clinical Pty Ltd to support its Phase 1b First-In-Human trial of PRP for advanced solid tumors. Avance brings 30 years of early-phase oncology expertise and access to Australian R&D tax rebates of up to 43.5%, promising accelerated trial execution.
On July 7, 2026 Propanc Biopharma executed an MOU with Avance Clinical Pty Ltd, committing both companies to collaborate on the delivery of the Phase 1b First-In-Human clinical trial of PRP for advanced solid tumors, marking a pivotal step from preclinical studies to human evaluation.
Avance Clinical offers over 30 years of early-phase oncology trial leadership across Australia, North America, Asia Pacific and Europe, leveraging rapid ethics approvals and a 43.5% Australian R&D tax rebate to provide expedited pathways for biotech clinical programs.
The Phase 1b study will assess PRP’s safety, tolerability, pharmacokinetics, immunogenicity and preliminary clinical activity in patients with advanced solid tumors, employing adaptive dose-escalation strategies in line with current regulatory expectations.
By partnering with Avance Clinical and capitalizing on its Melbourne-based subsidiary, Propanc aims to reduce development timelines and costs, generate critical clinical data for PRP and enhance its strategic position in the oncology therapeutics landscape.
